<DOC>
	<DOC>NCT02267902</DOC>
	<brief_summary>The objectives of this study are to evaluate the absolute bioavailability, and absorption and excretion of DA-1229, an IMP in clinical assessment for the treatment of T2DM. The oral and IV PK of DA-1229 will also be evaluated. The metabolism of DA-1229 may also be evaluated.</brief_summary>
	<brief_title>Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229</brief_title>
	<detailed_description />
	<criteria>Healthy males Age 18 to 55 BMI 18.0 to 30.0 kg/„é° History of any drug or alcohol abuse in the past 2years Regular alcohol consumption nin males &gt;21 units per week Current smokers and those who have smoked within the last 12months Radiation Exposure Positive drugs of abuse test result Positive HBsAg, HCV Ab, HIV results Serious adverse reaction or hypersensitivity to any drug of the formulation excipients Clinically significant allergy Donation of loss of blood within the previous 3 months Taking any prescribed or OTC drug or herbal remedies in the 14days before IMP administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Volunteers</keyword>
</DOC>